Patient Safety Technologies, Inc Form 10-Q August 15, 2011

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2011

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_

COMMISSION FILE NUMBER: 001-09727

PATIENT SAFETY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

13-3419202

(I.R.S. Employer Identification No.)

2 Venture Plaza, Suite 350, Irvine, CA 92618 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (949) 387-2277

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer "

Accelerated filer "

Non-accelerated filer " (Do not check if smaller reporting company) Smaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes "No x

The number of outstanding shares of the registrant's common stock, par value \$0.33 per share, as of August 1, 2011 was 33,660,255.

## PATIENT SAFETY TECHNOLOGIES, INC.

# FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2011

#### TABLE OF CONTENTS

|   | Page |
|---|------|
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS                    | 1    |
| HELPFUL INFORMATION   | 1    |
| PART I – FINANCIAL INFORMATION  | 2    |
| ITEM 1. FINANCIAL STATEMENTS  | 2    |
| Condensed Consolidated Balance Sheets                                   | 2    |
| Condensed Consolidated Statements of Operations                         | 3    |
| Condensed Consolidated Statements of Cash Flows                         | 4    |
| ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND |      |
| RESULTS OF OPERATIONS   | 15   |
| ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK      | 25   |
| ITEM 4. CONTROLS AND PROCEDURES   | 25   |
| PART II – OTHER INFORMATION   | 26   |
| ITEM 1. LEGAL PROCEEDINGS   | 26   |
| ITEM 1A. RISK FACTORS   | 26   |
| ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS     | 26   |
| ITEM 3. DEFAULTS UPON SENIOR SECURITIES                                 | 26   |
| ITEM 4. (REMOVED AND RESERVED)  | 26   |
| ITEM 5. OTHER INFORMATION   | 26   |
| ITEM 6. EXHIBITS  | 26   |
| SIGNATURES  | 27   |
|   |      |

#### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q (this "Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements relate to future events or our future performance and include, but are not limited to, statements concerning our business strategy, future commercial revenues, market growth, capital requirements, new product introductions, expansion plans and the adequacy of our funding. Other statements contained in this Report that are not historical facts are also forward-looking statements. You can sometimes identify forward-looking statements by our use of forward-looking words like "may," "will," "could," "should," "expects," "intends," "plans," "ant "believes," "estimates," "seeks," "predicts," "potential," or "continue" or the negative of these terms and other similar express and terminology.

We caution investors that any forward-looking statements presented in this Report, or that we may make orally or in writing from time to time, are based on the beliefs of, assumptions made by, and information currently available to us. Although we believe that the plans, objectives, expectations and intentions reflected in or suggested by our forward-looking statements are reasonable, those statements are based only on the current beliefs and assumptions of our management and on information currently available to us and, therefore, they involve uncertainties and risks as to what may happen in the future. Accordingly, we cannot guarantee that our plans, objectives, expectations or intentions will be achieved. Our actual results, performance (financial or operating) or achievements could differ from those expressed in or implied by any forward-looking statement in this report as a result of many known and unknown factors, many of which are beyond our ability to predict or control, and those differences may be material. These factors include, but are not limited to, those described under the caption "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2010 filed on April 14, 2011 and amended on April 29, 2011, including without limitation the following:

- the early stage of adoption of our Safety-Sponge® System and the need to expand adoption of our Safety-Sponge® System;
- the impact on our future revenues and cash flow from the ordering patterns of our exclusive distributor, Cardinal Health, Inc.;
- · our need for additional financing to support our business;
- · our reliance on third-party manufacturers, some of whom are sole-source suppliers, and on our exclusive distributor; and
- · any inability to successfully protect our intellectual property portfolio

This Report and all other written and oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in or referred to in this section.

Our forward-looking statements speak only as of the date they are made and should not be relied upon as representing our plans, objectives, expectations and intentions as of any subsequent date. Although we may elect to update or revise forward-looking statements at some time in the future, we specifically disclaim any obligation to do so, even if our plans, objectives, expectations or intentions change.

#### HELPFUL INFORMATION

As used throughout this quarterly report on Form 10-Q, the terms "the Company," "the registrant," "we," "us," and "our" me Patient Safety Technologies, Inc., a Delaware corporation, together with its consolidated subsidiary, SurgiCount Medical Inc., a California Corporation, unless the context otherwise requires.

Unless otherwise indicated, all statements presented in this quarterly report on Form 10-Q regarding the medical patient safety market, the market for surgical sponges, our market share, the cumulative number of surgical sponges used and number of procedures are internal estimates only.

Safety-Sponge®, SurgiCounter<sup>TM</sup> and Citadel<sup>TM</sup>, among others, are registered or unregistered trademarks of Patient Safety Technologies, Inc. (including its subsidiary).

1

#### PART I – FINANCIAL INFORMATION

#### ITEM 1. FINANCIAL STATEMENTS

## PATIENT SAFETY TECHNOLOGIES, INC.

#### Condensed Consolidated Balance Sheets

| Assets  |    | June 30,<br>2011<br>(Unaudited) |    | December 31,<br>2010 |  |
|---|----|---------------------------------|----|----------------------|--|
| Current assets:   |    |                                 |    |                      |  |
| Cash and cash equivalents   | \$ | 5,713,121                       | \$ | 1,896,034            |  |
| Restricted cash   |    | 223,630                         |    | 223,630              |  |
| Accounts receivable   |    | 675,594                         |    | 772,381              |  |
| Inventories, net  |    | 1,193,334                       |    | 1,110,832            |  |
| Prepaid expenses  |    | 43,813                          |    | 104,628              |  |
| Total current assets  |    | 7,849,492                       |    | 4,107,505            |  |
|   |    |                                 |    |                      |  |
| Property and equipment, net   |    | 932,641                         |    | 979,833              |  |
| Goodwill  |    | 1,832,027                       |    | 1,832,027            |  |
| Patents, net  |    | 2,626,612                       |    | 2,789,083            |  |
| Other assets  |    | 52,213                          |    | 39,038               |  |
| Total assets  | \$ | 13,292,985                      | \$ | 9,747,486            |  |
| Liabilities and Stockholders' Equity  |    |                                 |    |                      |  |
| Current liabilities   |    |                                 |    |                      |  |
| Accounts payable  | \$ | 1,674,531                       | \$ | 2,605,669            |  |
| Warrant derivative liability  |    | 767,060                         |    | 991,682              |  |
| Deferred revenue  |    | 375,950                         |    | 1,477,720            |  |
| Accrued liabilities   |    | 419,354                         |    | 942,472              |  |
| Total current liabilities   |    | 3,236,895                       |    | 6,017,543            |  |
| Commitments and contingencies (Note 12)   |    |                                 |    |                      |  |
| Stockholders' equity:   |    |                                 |    |                      |  |
| Series A preferred stock, \$1.00 par value, cumulative 7% dividend: 1,000,000 shares authorized; 10,950 issued and outstanding at June 30, 2011 and December 31, 2010; (Liquidation preference of \$1.1 million at  |    |                                 |    |                      |  |
| June 30, 2011 and December 31, 2010)  |    | 10,950                          |    | 10,950               |  |
| Series B convertible preferred stock, \$1.00 par value, cumulative 7% dividend: 150,000 shares authorized; 63,694 issued and outstanding at June 30, 2011 and 61,589 issued and outstanding at December 31, 2010; (Liquidation preference of \$6.4 million at June 30, 2011 and \$6.2 million | ;  |                                 |    |                      |  |
| at December 31, 2010)   |    | 63,694                          |    | 61,589               |  |
| Common stock, \$0.33 par value: 100,000,000 shares authorized; 33,520,255 shares issued and outstanding at June 30, 2011 and 23,956,063   |    | 11,061,684                      |    | 7,905,501            |  |

shares issued and outstanding at December 31, 2010

| Additional paid-in capital                 | 56,570,861       | 52,356,930   |
|--|------------------|--------------|
| Accumulated deficit                        | (57,651,099)     | (56,605,027) |
| Total stockholders' equity                 | 10,056,090       | 3,729,943    |
| Total liabilities and stockholders' equity | \$ 13,292,985 \$ | 9,747,486    |

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

## PATIENT SAFETY TECHNOLOGIES, INC. Condensed Consolidated Statements of Operations (Unaudited)

|                 |              | Three Months Ended June 30, |              | Six Months Ended<br>June 30, |  |
|-----------------|--------------|-----------------------------|--------------|------------------------------|--|
|                 | 2011         | 2010                        | 2011         | 2010                         |  |
| Revenues        | \$ 2,568,770 | \$ 3,765,517                | \$ 4,539,426 | \$ 6,130,337                 |  |
| Cost of revenue | 1,296,130    | 1,790,360                   | 2,337,231    | 2,879,248                    |  |
| Gross profit    | 1,272,640    | 1,975,157                   | 2,202,195    | 3,251,089                    |  |